CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Remdesivir

瑞德西韦 杂质对照品Remdesivir Impurities

29 个杂质条目29 impurity entries

本页汇总 瑞德西韦 的 29 个杂质对照品条目。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 29 impurity reference standards of Remdesivir. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 瑞德西韦(Remdesivir)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesDevelopment, validation and forced degradation studies of green liquid chromatographic method for determination of remdesivir in bulk drug and pharmaceutical formulation
    Pakistan journal of pharmaceutical sciences · 2023 · Abdul Samad H et al.  ·  PMID 36967508
  2. 杂质研究Impurity studiesEco-friendly stability-indicating HPTLC micro-determination of the first FDA approved SARS-CoV-2 antiviral prodrug Remdesivir: Study of degradation kinetics and structural elucidation of the degradants using HPTLC-MS
    Sustainable chemistry and pharmacy · 2022 · Abo-Gharam AH, El-Kafrawy DS  ·  PMID 35720509  ·  DOI
  3. 杂质研究Impurity studiesA Novel Liquid Chromatographic Method for the Quantitative Determination of Degradation Products in Remdesivir Injectable Drug product
    Journal of chromatographic science · 2022 · Reddy HR et al.  ·  PMID 33948643  ·  DOI

合成路线参考Reported synthetic routes

以下为公开文献中报道的合成方法(题录信息)。标题多已点明关键反应,可据此查阅原文了解完整路线与工艺条件。Published synthetic approaches. Titles usually name the key transformation; consult the original articles for full routes.

  • 合成方法SynthesisRemdesivir triphosphate is a valid substrate to initiate synthesis of DNA primers by human PrimPol
    DNA repair · 2024 · Jiménez-Juliana M et al.  ·  PMID 39378561  ·  DOI
  • 合成方法SynthesisSynthesis of Remdesivir Derivate as a Generation of Anti-COVID-19 Drugs Through Acetylation Reactions
    Archives of Razi Institute · 2023 · Sumardi R et al.  ·  PMID 38828177  ·  DOI

瑞德西韦 —— 原料药与杂质对照品Remdesivir — drug substance & impurities

共 30 个条目(含原料药本体)30 items incl. the drug substance
Remdesivir structure
原料药 APIAPI
瑞德西韦Remdesivir
Remdesivir
CAS No.1809249-37-3
Chemical FormulaC27H35N6O8P
Purity>95%询价On request
10mg25mg50mg100mg
Remdesivir-d1A structure
—
瑞德西韦-d1ARemdesivir-d1A
Remdesivir-d1A
CAS No.2440242-46-4
Chemical FormulaC27H34DN6O8P
Purity>95%询价On request
10mg25mg50mg100mg
Remdesivir Impurity 1 structure
1
瑞德西韦杂质1Remdesivir Impurity 1
Remdesivir Impurity 1
CAS No.159326-68-8
Chemical FormulaC6H6N4
Purity>95%询价On request
10mg25mg50mg100mg
Miglitol Impurity N1 structure
N1
米格列醇杂质N1Miglitol Impurity N1
Miglitol Impurity N1
CAS No.1459288-93-7
Chemical FormulaC23H28O8S
Purity>95%现货In stock
10mg25mg50mg100mg
Remdesivir Impurity 2 structure
2
瑞德西韦杂质2Remdesivir Impurity 2
Remdesivir Impurity 2
CAS No.1770840-43-1
Chemical FormulaC6H5IN4
Purity>95%询价On request
10mg25mg50mg100mg
Remdesivir Impurity 3 structure
3
瑞德西韦杂质3Remdesivir Impurity 3
Remdesivir Impurity 3
CAS No.55094-52-5
Chemical FormulaC26H26O5
Purity>95%询价On request
10mg25mg50mg100mg
Remdesivir Impurity 4 structure
4
瑞德西韦杂质4Remdesivir Impurity 4
Remdesivir Impurity 4
CAS No.1911578-73-8
Chemical FormulaC32H32N4O5
Purity>95%询价On request
10mg25mg50mg100mg
Remdesivir Impurity 5 structure
5
瑞德西韦杂质5Remdesivir Impurity 5
Remdesivir Impurity 5
CAS No.1355357-49-1
Chemical FormulaC33H31N5O4
Purity>95%询价On request
10mg25mg50mg100mg
Remdesivir Impurity 6 structure
6
瑞德西韦杂质6Remdesivir Impurity 6
Remdesivir Impurity 6
CAS No.1191237-69-0
Chemical FormulaC12H13N5O4
Purity>95%询价On request
10mg25mg50mg100mg
Remdesivir Impurity 7 structure
7
瑞德西韦杂质7Remdesivir Impurity 7
Remdesivir Impurity 7
CAS No.1191237-80-5
Chemical FormulaC15H17N5O4
Purity>95%询价On request
10mg25mg50mg100mg
Remdesivir Impurity 8 structure
8
瑞德西韦杂质8Remdesivir Impurity 8
Remdesivir Impurity 8
CAS No.946511-97-3
Chemical FormulaC9H19NO2·HCl
Purity>95%询价On request
10mg25mg50mg100mg
Remdesivir Impurity 9 structure
9
瑞德西韦杂质9Remdesivir Impurity 9
Remdesivir Impurity 9
CAS No.1439900-56-7
Chemical FormulaC21H27N2O7P
Purity>95%询价On request
10mg25mg50mg100mg
Remdesivir Impurity 10 structure
10
瑞德西韦杂质10Remdesivir Impurity 10
Remdesivir Impurity 10
CAS No.1354823-36-1
Chemical FormulaC21H27N2O7P
Purity>95%询价On request
10mg25mg50mg100mg
Remdesivir Impurity 11 structure
11
瑞德西韦杂质11Remdesivir Impurity 11
Remdesivir Impurity 11
CAS No.1355149-45-9
Chemical FormulaC12H16N5O13P3
Purity>95%询价On request
10mg25mg50mg100mg
Remdesivir Impurity 12 structure
12
瑞德西韦杂质12Remdesivir Impurity 12
Remdesivir Impurity 12
CAS No.1355049-95-4
Chemical FormulaC12H13N5O4
Purity>95%询价On request
10mg25mg50mg100mg
Remdesivir Impurity 14 structure
14
瑞德西韦杂质14Remdesivir Impurity 14
Remdesivir Impurity 14
CAS No.2096981-79-0
Chemical FormulaC9H19NO2·HCl
Purity>95%询价On request
10mg25mg50mg100mg
Remdesivir Impurity 15 structure
15
瑞德西韦杂质15Remdesivir Impurity 15
Remdesivir Impurity 15
CAS No.2096985-18-9
Chemical FormulaC21H27N2O7P
Purity>95%询价On request
10mg25mg50mg100mg
Remdesivir Impurity 16 structure
16
瑞德西韦杂质16Remdesivir Impurity 16
Remdesivir Impurity 16
CAS No.2093124-22-0
Chemical FormulaC21H27N2O7P
Purity>95%询价On request
10mg25mg50mg100mg
Remdesivir Impurity 20 structure
20
瑞德西韦杂质20Remdesivir Impurity 20
Remdesivir Impurity 20
CAS No.1911578-75-0
Chemical FormulaC27H35N6O8P
Purity>95%询价On request
10mg25mg50mg100mg
Remdesivir Impurity 26 structure
26
瑞德西韦杂质26Remdesivir Impurity 26
Remdesivir Impurity 26
CAS No.1355049-92-1
Chemical FormulaC15H23ClNO4P
Purity>95%询价On request
10mg25mg50mg100mg
Remdesivir Impurity 27 structure
27
瑞德西韦杂质27Remdesivir Impurity 27
Remdesivir Impurity 27
CAS No.1354823-37-2
Chemical FormulaC21H27N2O7P
Purity>95%询价On request
10mg25mg50mg100mg
Remdesivir Impurity 30 structure
30
瑞德西韦杂质30Remdesivir Impurity 30
Remdesivir Impurity 30
CAS No.1911578-99-8
Chemical FormulaC21H23F5NO5P
Purity>95%询价On request
10mg25mg50mg100mg
Remdesivir Impurity 40 structure
40
瑞德西韦杂质40Remdesivir Impurity 40
Remdesivir Impurity 40
CAS No.1355049-94-3
Chemical FormulaC32H32N4O5
Purity>95%询价On request
10mg25mg50mg100mg
Remdesivir Impurity 45 structure
45
瑞德西韦杂质45Remdesivir Impurity 45
Remdesivir Impurity 45
CAS No.1911578-74-9
Chemical FormulaC12H14N5O7P
Purity>95%询价On request
10mg25mg50mg100mg
Remdesivir Impurity 52 structure
52
瑞德西韦杂质52Remdesivir Impurity 52
Remdesivir Impurity 52
CAS No.1256490-31-9
Chemical FormulaC18H21N2O7P
Purity>95%询价On request
10mg25mg50mg100mg
Remdesivir Impurity 61 structure
61
瑞德西韦杂质61Remdesivir Impurity 61
Remdesivir Impurity 61
CAS No.2954791-12-7
Chemical FormulaC18H27NO6
Purity>95%询价On request
10mg25mg50mg100mg
Remdesivir Impurity 62 structure
62
瑞德西韦杂质62Remdesivir Impurity 62
Remdesivir Impurity 62
CAS No.78614-47-8
Chemical FormulaC11H21NO6
Purity>95%询价On request
10mg25mg50mg100mg
Remdesivir Impurity 63 structure
63
瑞德西韦杂质63Remdesivir Impurity 63
Remdesivir Impurity 63
CAS No.1911578-77-2
Chemical FormulaC12H15N5O10P2
Purity>95%询价On request
10mg25mg50mg100mg
Remdesivir Impurity 66 structure
66
瑞德西韦杂质66Remdesivir Impurity 66
Remdesivir Impurity 66
CAS No.2848679-62-7
Chemical FormulaC12H13N5O4
Purity>95%询价On request
10mg25mg50mg100mg
Remdesivir Impurity 67 structure
67
瑞德西韦杂质67Remdesivir Impurity 67
Remdesivir Impurity 67
CAS No.2620657-26-1
Chemical FormulaC38H38N8O5
Purity>95%询价On request
10mg25mg50mg100mg

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

瑞德西韦 —— 研究文献与合成路线Remdesivir — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 瑞德西韦 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Remdesivir. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. Eco-friendly stability-indicating HPTLC micro-determination of the first FDA approved SARS-CoV-2 antiviral prodrug Remdesivir: Study of degradation kinetics and structural elucidation of the degradants using HPTLC-MS
    Abo-Gharam AH, El-Kafrawy DS · Sustainable chemistry and pharmacy · 2022 · 被引 11cited 11
  2. Development, validation and forced degradation studies of green liquid chromatographic method for determination of remdesivir in bulk drug and pharmaceutical formulation
    Abdul Samad H, Nadir Ali S, Qayoom A, et al. · Pakistan journal of pharmaceutical sciences · 2023
  3. A Novel Liquid Chromatographic Method for the Quantitative Determination of Degradation Products in Remdesivir Injectable Drug product
    Reddy HR, Pratap SR, Chandrasekhar N, et al. · Journal of chromatographic science · 2022 · 被引 7cited 7
  4. Favipiravir, remdesivir, and lopinavir: metabolites, degradation products and their analytical methods
    Hoseininezhad-Namin MS, Rahimpour E, Jouyban A · Drug metabolism reviews · 2024 · 被引 2cited 2
  5. Wavelets Synchronous Spectrofluorimetric Determination of Remdesivir in the Presence of Its Alkaline-Induced Degradation Product
    Saeda HA, Abdel-Monem AH, El-Attar AAM, et al. · 2026
  6. A systemic approach to estimate and validate RP-HPLC assay method for remdesivir and favipiravir in capsule dosage form
    Khan NU, Iqbal M, Khan BA · PloS one · 2025 · 被引 1cited 1

合成路线文献Synthetic-route papers

  1. Synthesis and antitumoral evaluation of 3',4'-unsaturated nucleoside analogues bearing a chlorinated remdesivir-like base
    Wang S, Yang J, Yang X, et al. · Bioorganic chemistry · 2026
  2. Copy-back RNA synthesis by coronavirus polymerase requires helicase activity and is stimulated by remdesivir and molnupiravir
    Rakib A, Das A, Bera SC, et al. · Science advances · 2026
  3. Remdesivir triphosphate is a valid substrate to initiate synthesis of DNA primers by human PrimPol
    Jiménez-Juliana M, Martínez-Jiménez MI, Blanco L · DNA repair · 2024

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

瑞德西韦 杂质谱研究要点Remdesivir — impurity profiling notes

下面这些是拿到 瑞德西韦 的 30 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 30 impurity entries for Remdesivir, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances